Jessica Ibbitson

Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA.

Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO.

Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France.

NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Sapiens Steering Brain Stimulation BV develops medical devices. The company was founded by Sjaak Deckers in 2011 and is headquartered in Eindhoven, the Netherlands.

Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.

Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany.

HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France.

Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China.

Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California.

Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland.

Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands.

T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany.

Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022.

Pathalys Pharma, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing advanced therapeutics to manage end-stage kidney disease. The company is based in Raleigh, NC. The company's initial asset is Upacicalcet, a novel calcimimetic that has the potential to improve the treatment of secondary hyperparathyroidism in hemodialysis patients. Pathalys Pharma continues to identify other high priority needs and potential solutions for patients with end-stage kidney disease. The company was founded by Ashwin Ram, Mahesh Krishnan, Jay P. Shepard, Brian Taylor Slingsby. The CEO is Neal F. Fowler.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.